Regen BioPharma, Inc. Receives First Phase of Confirmatory Study - Regen BioPharma, Inc. (OTCPK:RGBP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders.
The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.
"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."
"We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on," says Dr. David Koos, Chairman and CEO of the company. CONTINUED… Read this full press release and more news for RGBP at: https://regenbiopharmainc.com/company-news1/